These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 25779854)

  • 1. Prognostic Factors in Lobar World Health Organization Grade II Astrocytomas.
    Waqar M; Hanif S; Brodbelt AR; Rathi N; Das K; Zakaria R; Walker C; Jenkinson MD
    World Neurosurg; 2015 Jul; 84(1):154-62. PubMed ID: 25779854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Resection on Survival of Isocitrate Dehydrogenase 1-Mutated World Health Organization Grade II Astrocytoma After Malignant Progression.
    Grau SJ; Hampl JA; Kohl AC; Timmer M; Duval IV; Blau T; Ruge MI; Goldbrunner RH
    World Neurosurg; 2017 Jul; 103():180-185. PubMed ID: 28377251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of the extent of resection in supratentorial WHO grade II astrocytomas stratified for IDH1 mutation status: a single-center volumetric analysis.
    Jungk C; Scherer M; Mock A; Capper D; Radbruch A; von Deimling A; Bendszus M; Herold-Mende C; Unterberg A
    J Neurooncol; 2016 Sep; 129(2):319-28. PubMed ID: 27344556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-free survival and prolonged postrecurrence survival.
    Thon N; Eigenbrod S; Kreth S; Lutz J; Tonn JC; Kretzschmar H; Peraud A; Kreth FW
    Cancer; 2012 Jan; 118(2):452-60. PubMed ID: 21717448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KPNA2 predicts long term survival in patients with anaplastic oligoastrocytomas.
    Gousias K; Niehusmann P; Gielen G; Simon M; Boström J
    J Clin Neurosci; 2014 Oct; 21(10):1719-24. PubMed ID: 24929863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IDH1 mutation is prognostic for diffuse astrocytoma but not low-grade oligodendrogliomas in patients not treated with early radiotherapy.
    Iwadate Y; Matsutani T; Hirono S; Ikegami S; Shinozaki N; Saeki N
    J Neurooncol; 2015 Sep; 124(3):493-500. PubMed ID: 26243269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proposed therapeutic strategy for adult low-grade glioma based on aggressive tumor resection.
    Nitta M; Muragaki Y; Maruyama T; Ikuta S; Komori T; Maebayashi K; Iseki H; Tamura M; Saito T; Okamoto S; Chernov M; Hayashi M; Okada Y
    Neurosurg Focus; 2015 Jan; 38(1):E7. PubMed ID: 25599276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection.
    Beiko J; Suki D; Hess KR; Fox BD; Cheung V; Cabral M; Shonka N; Gilbert MR; Sawaya R; Prabhu SS; Weinberg J; Lang FF; Aldape KD; Sulman EP; Rao G; McCutcheon IE; Cahill DP
    Neuro Oncol; 2014 Jan; 16(1):81-91. PubMed ID: 24305719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.
    Hartmann C; Hentschel B; Wick W; Capper D; Felsberg J; Simon M; Westphal M; Schackert G; Meyermann R; Pietsch T; Reifenberger G; Weller M; Loeffler M; von Deimling A
    Acta Neuropathol; 2010 Dec; 120(6):707-18. PubMed ID: 21088844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined IDH1 mutation and MGMT methylation status on long-term survival of patients with cerebral low-grade glioma.
    Tanaka K; Sasayama T; Mizukawa K; Takata K; Sulaiman NS; Nishihara M; Kohta M; Sasaki R; Hirose T; Itoh T; Kohmura E
    Clin Neurol Neurosurg; 2015 Nov; 138():37-44. PubMed ID: 26276726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Secondary Glioblastoma: Molecular and Clinical Factors That Affect Outcome After Malignant Progression of a Lower Grade Tumor.
    Gessler F; Zappi J; Konczalla J; Bernstock JD; Forster MT; Wagner M; Mittelbronn M; Seifert V; Senft C
    World Neurosurg; 2017 Jun; 102():49-55. PubMed ID: 28263929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment outcome of IDH1/2 wildtype CNS WHO grade 4 glioma histologically diagnosed as WHO grade II or III astrocytomas.
    Keric N; Krenzlin H; Kalasauskas D; Freyschlag CF; Schnell O; Misch M; von der Brelie C; Gempt J; Krigers A; Wagner A; Lange F; Mielke D; Sommer C; Brockmann MA; Meyer B; Rohde V; Vajkoczy P; Beck J; Thomé C; Ringel F
    J Neurooncol; 2024 Mar; 167(1):133-144. PubMed ID: 38326661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pleomorphic xanthoastrocytoma: long-term results of surgical treatment and analysis of prognostic factors.
    Gallo P; Cecchi PC; Locatelli F; Rizzo P; Ghimenton C; Gerosa M; Pinna G
    Br J Neurosurg; 2013 Dec; 27(6):759-64. PubMed ID: 23514331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. No prognostic value of IDH1 mutations in a series of 100 WHO grade II astrocytomas.
    Ahmadi R; Stockhammer F; Becker N; Hohlen K; Misch M; Christians A; Dictus C; Herold-Mende C; Capper D; Unterberg A; von Deimling A; Wick W; Hartmann C
    J Neurooncol; 2012 Aug; 109(1):15-22. PubMed ID: 22528790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New clinical, pathological and molecular prognostic models and calculators in patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951.
    Gorlia T; Delattre JY; Brandes AA; Kros JM; Taphoorn MJ; Kouwenhoven MC; Bernsen HJ; Frénay M; Tijssen CC; Lacombe D; van den Bent MJ
    Eur J Cancer; 2013 Nov; 49(16):3477-85. PubMed ID: 23896377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Clinical, Tumor, and Treatment Characteristics With Seizure Control in Patients With
    Bruno F; Pellerino A; Conti Nibali M; Pronello E; Cofano F; Rossi M; Levis M; Bertero L; Soffietti R; Cassoni P; Garbossa D; Bello L; Rudà R
    Neurology; 2024 May; 102(10):e209352. PubMed ID: 38684041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-grade astrocytomas: the prognostic value of fibrillary, gemistocytic, and protoplasmic tumor histology.
    Babu R; Bagley JH; Park JG; Friedman AH; Adamson C
    J Neurosurg; 2013 Aug; 119(2):434-41. PubMed ID: 23662821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preoperative prognostic classification system for hemispheric low-grade gliomas in adults.
    Chang EF; Smith JS; Chang SM; Lamborn KR; Prados MD; Butowski N; Barbaro NM; Parsa AT; Berger MS; McDermott MM
    J Neurosurg; 2008 Nov; 109(5):817-24. PubMed ID: 18976070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic and radiographic correlates of a prospectively collected molecularly profiled cohort of IDH1/2-wildtype astrocytomas.
    Lin AL; Rosenblum M; Mellinghoff IK; Tabar VS; Ogilvie S; Schaff L; Yang TJ; Young RJ; Taylor BS; Jonsson P; Bale TA
    Brain Pathol; 2020 May; 30(3):653-660. PubMed ID: 31984581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival of diffuse astrocytic glioma, IDH1/2 wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria.
    Tesileanu CMS; Dirven L; Wijnenga MMJ; Koekkoek JAF; Vincent AJPE; Dubbink HJ; Atmodimedjo PN; Kros JM; van Duinen SG; Smits M; Taphoorn MJB; French PJ; van den Bent MJ
    Neuro Oncol; 2020 Apr; 22(4):515-523. PubMed ID: 31637414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.